☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
NewAmsterdam Pharma
NewAmsterdam Pharma Reports the Completion of Patient Enrollment in P-III trial (BROOKYLN) of Obicetrapib for Heterozygous Familia...
April 25, 2023
NewAmsterdam Pharma Initiates P-II Dose-Finding Study of Obicetrapib for the Treatment of Dyslipidemia
October 6, 2022
NewAmsterdam Pharma to Go Public via FLAC SPAC Merger for ~$326M
July 26, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.
